Joint venture contract with Zydus Cadila to be amended for the production of active pharmaceutical ingredients (API)
Transfer of chemical production from facilities in Singen (Germany) and Linz (Austria) to India until 2011
Singen and Linz will focus on pharmaceutical production
Nycomed and Cadila Healthcare have signed a letter agreement with the intent to amend their existing joint venture agreement to include the chemical production of active pharmaceutical ingredients (APIs) by the joint venture company Zydus Nycomed in India......
Total net turnover increases by 3.0% to € 3,497.4 million
31.0% increase in adjusted EBITDA
Instanyl™ filed for European approval
Own Pantoprazole generic as response to US at-risk launch
Major progress in US out-licensing strategy
Acquisition of Bradley Pharmaceuticals successfully closed
The financial results reported in this press release are related to Nycomed S......
Nycomed creates a leading specialty pharmaceutical player in dermatology
Enhanced platform for in-licensing and co-promotion of dermatology products
Combined US dermatology sales of $450 million
Today, Nycomed successfully completed the acquisition of Bradley Pharmaceuticals, a company focused on niche therapeutic markets in the United States......
Legal counsel to be integral part of Executive Committee
Nycomed’s Board of Directors has appointed Michael Kuner Executive Vice President Legal. He joins the company’s Executive Committee with immediate effect......
-Own presence in Venezuela to further enhance strong Latin American presence
-Nycomed strategy to participate in high-growth markets and offer licensing opportunities to partners
Nycomed is about to establish its own marketing and sales organisation in Venezuela......
Own generic of Pantoprazole introduced to US market
Move in response to at-risk launch of generic Pantoprazole in the United States
Nycomed and Wyeth remain convinced of valididity and enforcability of their patent and continue to pursue litigation
Nycomed and its licence holder Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), today announced the U......
Sepracor acquires exclusive development, marketing and commercialisation rights to the Ciclesonide franchise in the United States
Ciclesonide is the active ingredient in the ALVESCO® Inhalation Aerosol for asthma and the Omnaris™ Nasal Spray for allergic rhinitis
ALVESCO® and Omnaris™ are FDA-approved and are on track to be launched in 2008
Agreement is in alignment with Nycomed’s strategy to cooperate with the best partners for its key brands in the United States
Partnership between Nycomed and Sepracor provides a good strategic fit for both companies
Nycomed has granted Sepracor, Inc......
ALVESCO® (ciclesonide) Inhalation Aerosol approved by FDA for the maintenance and prophylactic treatment of asthma in patients 12 years of age and older
ALVESCO® will be commercialised by U......
Surgical patch TachoSil® planned to enter US market with partner Baxter
Important milestone for Nycomed’s partnership strategy for the US market
Nycomed grants Baxter International Inc......
Marketing authorisation application filed for Europe through the Centralised Procedure
Treatment aimed at opioid tolerant patients with cancer experiencing breakthrough pain
Strengthening the Nycomed pain control portfolio
Nycomed filed a marketing authorisation application with the European Medicines Agency (EMEA) for an intranasal fentanyl spray in Europe on December 7, 2007......